Victory Capital Management Inc. Has $10.33 Million Stock Position in Alkermes plc $ALKS

Victory Capital Management Inc. increased its holdings in Alkermes plc (NASDAQ:ALKS) by 43.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 344,202 shares of the company’s stock after acquiring an additional 103,749 shares during the period. Victory Capital Management Inc. owned about 0.21% of Alkermes worth $10,326,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of ALKS. Norges Bank acquired a new position in Alkermes in the 2nd quarter valued at approximately $53,326,000. BNP Paribas Financial Markets grew its holdings in shares of Alkermes by 787.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 1,135,478 shares of the company’s stock valued at $32,486,000 after acquiring an additional 1,007,488 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Alkermes in the third quarter worth $27,040,000. American Century Companies Inc. raised its holdings in shares of Alkermes by 20.2% during the third quarter. American Century Companies Inc. now owns 4,397,471 shares of the company’s stock worth $131,924,000 after acquiring an additional 740,248 shares in the last quarter. Finally, Holocene Advisors LP raised its holdings in shares of Alkermes by 31.2% during the second quarter. Holocene Advisors LP now owns 2,853,768 shares of the company’s stock worth $81,646,000 after acquiring an additional 679,166 shares in the last quarter. 95.21% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, SVP Christian Todd Nichols sold 6,000 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $30.00, for a total transaction of $180,000.00. Following the completion of the sale, the senior vice president owned 109,769 shares in the company, valued at $3,293,070. This represents a 5.18% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Shane Cooke sold 61,200 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $34.57, for a total value of $2,115,684.00. Following the completion of the sale, the director directly owned 103,744 shares in the company, valued at $3,586,430.08. This trade represents a 37.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 157,434 shares of company stock valued at $5,305,794. 4.40% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several brokerages have weighed in on ALKS. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Alkermes in a research report on Monday, December 29th. HC Wainwright reissued a “neutral” rating and issued a $43.00 price target on shares of Alkermes in a research note on Thursday, February 26th. Wolfe Research assumed coverage on Alkermes in a report on Monday, February 23rd. They issued an “outperform” rating and a $45.00 price objective on the stock. Royal Bank Of Canada reduced their target price on shares of Alkermes from $47.00 to $45.00 and set an “outperform” rating for the company in a research note on Thursday, February 26th. Finally, Wall Street Zen lowered shares of Alkermes from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $44.07.

Alkermes Stock Up 0.1%

Shares of Alkermes stock opened at $27.77 on Thursday. Alkermes plc has a 12-month low of $25.17 and a 12-month high of $36.32. The stock has a 50 day moving average price of $31.60 and a two-hundred day moving average price of $30.21. The stock has a market capitalization of $4.63 billion, a P/E ratio of 19.42, a PEG ratio of 6.92 and a beta of 0.53.

Alkermes (NASDAQ:ALKS) last issued its quarterly earnings data on Wednesday, February 25th. The company reported $0.29 earnings per share for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.14). Alkermes had a return on equity of 14.91% and a net margin of 16.37%.The firm had revenue of $384.55 million during the quarter, compared to analyst estimates of $380.44 million. During the same quarter in the previous year, the firm posted $1.05 earnings per share. Alkermes’s quarterly revenue was down 10.6% compared to the same quarter last year. Alkermes has set its FY 2026 guidance at -0.798–0.680 EPS. Sell-side analysts anticipate that Alkermes plc will post 1.31 earnings per share for the current year.

About Alkermes

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.